Brooks, Moore & Associates, Inc. Abb Vie Inc. Transaction History

Brooks, Moore & Associates, Inc.

$168 Million
Q3 2024

A detailed history of Brooks, Moore & Associates, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Brooks, Moore & Associates, Inc. holds 28,543 shares of ABBV stock, worth $5.14 Million. This represents 3.35% of its overall portfolio holdings.

Number of Shares

28,543

Previous 28,696 0.53%

Holding current value

$5.14 Million

Previous $4.92 Million 14.53%

% of portfolio

3.35%

Previous 3.18%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$163.84 - $199.33 $25,067 - $30,497	-153 Reduced 0.53%	28,543 $5.64 Million
Q1 2024 May 14, 2024	SELL	$159.82 - $182.1 $13,584 - $15,478	-85 Reduced 0.3%	28,696 $5.23 Million
Q4 2023 Feb 15, 2024	SELL	$137.6 - $154.97 $27,520 - $30,994	-200 Reduced 0.69%	28,781 $4.46 Million
Q3 2023 Nov 15, 2023	SELL	$133.59 - $154.65 $180,212 - $208,622	-1,349 Reduced 4.45%	28,981 $4.32 Million
Q2 2023 Aug 15, 2023	SELL	$132.51 - $164.9 $64,664 - $80,471	-488 Reduced 1.58%	30,330 $4.09 Million
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $84,596 - $97,425	585 Added 1.93%	30,818 $4.91 Million
Q4 2022 Feb 03, 2023	SELL	$138.31 - $165.87 $928,475 - $1.11 Million	-6,713 Reduced 18.17%	30,233 $4.89 Million
Q3 2022 Nov 17, 2022	BUY	$134.21 - $153.93 $119,715 - $137,305	892 Added 2.47%	36,946 $4.96 Million
Q2 2022 Aug 04, 2022	SELL	$137.62 - $174.96 $211,109 - $268,388	-1,534 Reduced 4.08%	36,054 $5.52 Million
Q1 2022 May 03, 2022	SELL	$131.98 - $163.75 $369,544 - $458,500	-2,800 Reduced 6.93%	37,588 $6.09 Million
Q4 2021 Feb 04, 2022	BUY	$107.43 - $135.93 $113,875 - $144,085	1,060 Added 2.7%	40,388 $5.47 Million
Q3 2021 Nov 08, 2021	SELL	$106.4 - $120.78 $494,228 - $561,023	-4,645 Reduced 10.56%	39,328 $4.24 Million
Q2 2021 Jul 21, 2021	SELL	$105.21 - $117.21 $39,453 - $43,953	-375 Reduced 0.85%	43,973 $4.95 Million
Q1 2021 May 04, 2021	BUY	$102.3 - $112.62 $242,962 - $267,472	2,375 Added 5.66%	44,348 $4.8 Million
Q4 2020 Feb 08, 2021	BUY	$80.49 - $108.67 $166,292 - $224,512	2,066 Added 5.18%	41,973 $4.5 Million
Q3 2020 Nov 02, 2020	BUY	$85.91 - $100.83 $577,229 - $677,476	6,719 Added 20.25%	39,907 $3.5 Million
Q2 2020 Aug 10, 2020	BUY	$73.37 - $98.18 $173,960 - $232,784	2,371 Added 7.69%	33,188 $3.26 Million
Q1 2020 Apr 22, 2020	BUY	$64.5 - $97.79 $136,095 - $206,336	2,110 Added 7.35%	30,817 $2.35 Million
Q4 2019 Jan 30, 2020	BUY	$72.13 - $90.25 $72 - $90	1 Added 0.0%	28,707 $2.54 Million
Q3 2019 Oct 25, 2019	BUY	$62.98 - $75.72 $499,053 - $600,005	7,924 Added 38.13%	28,706 $2.17 Million
Q2 2019 Aug 09, 2019	BUY	$65.7 - $83.98 $208,597 - $266,636	3,175 Added 18.03%	20,782 $1.51 Million
Q1 2019 Apr 24, 2019	BUY	$77.14 - $90.79 $92,568 - $108,948	1,200 Added 7.31%	17,607 $1.42 Million
Q4 2018 Feb 06, 2019	BUY	$77.85 - $96.01 $1.28 Million - $1.58 Million	16,407 New	16,407 $1.51 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brooks, Moore & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brooks, Moore & Associates, Inc. with notifications on news.

Account

Brooks, Moore & Associates, Inc. Abb Vie Inc. Transaction History